Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

Onconova Therapeutics (NASDAQ: ONTX) was reduced by Zacks Investment Research¬† from a “buy” ranking to a “hold” ranking in a research note issued to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It concentrates on finding and also developing little molecule medication prospects to deal with cancer. The Firm‘s products under different stages of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research analysts also just recently commented on the firm. Noble Financial editioned a “buy” rating and provided a $11.00 cost objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “buy” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving typical cost of $2.90 and also a two-hundred day moving typical price of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) revenues per share for the quarter, covering experts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and an unfavorable internet margin of 8,294.27%. The firm had revenue of $0.06 million throughout the quarter, contrasted to the consensus quote of $0.06 million. During the same quarter in the previous year, the firm published ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will upload -1.18 EPS for the current year.

A variety of hedge funds have lately bought and sold shares of ONTX. GSA Funding Allies LLP acquired a new position in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Management LP bought a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP purchased a brand-new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and also other institutional capitalists possess 13.36% of the company’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the recognition and advancement of oncology therapeutics. It focuses on discovering as well as developing tiny molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a complimentary duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To find out more about research offerings from Zacks Investment Research, go to Zacks.com.

This instantaneous information alert was generated by narrative scientific research technology and also financial data from Market in order to supply visitors with the fastest as well as most accurate reporting. This tale was reviewed by Market’s content group prior to publication.¬†



Before you consider Onconova Therapeutics, you’ll intend to hear this.

Market monitors Wall Street’s top-rated and also best carrying out research analysts and the stocks they advise to their clients on a daily basis. Market has identified the 5 stocks that cover analysts are silently whispering to their customers to get currently prior to the broader market catches on … as well as Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics currently has a “Buy” score among experts, top-rated experts think these five stocks are much better gets.